1	Menopausal vasomotor symptoms and
2	subclinical atherosclerotic cardiovascular
3	disease – a population-based study
4	Short title: Vasomotor symptoms and subclinical atherosclerosis
5 6	Subcliffical attref0501610515
7 8 9	Sigrid Nilsson MD PhD Student ^{1*} , Angelika Qvick MD PhD student ² , Moa Henriksson Medical student PhD student ¹ , Sofia Sederholm Lawesson MD PhD ³ , Anna-Clara Spetz Holm MD PhD ¹ , Karin Leander MPH PhD ² .
10 11	¹ Department of Obstetrics and Gynecology in Linköping, and Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.
12 13	² Unit of Cardiovascular and Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
14 15 16	³ Department of Cardiology, and Department of Health, Medicine and Caring Sciences, Linkoping University, Linkoping, Sweden.
17	*Corresponding author:
18	Sigrid Nilsson
19 20	Department of Obstetrics and Gynecology in Linköping, and Department of Biomedical and Clinical Sciences, Linköping University, Linköping
21	58185 Linköping, Sweden.
22	E-mail: sigrid.nilsson@liu.se
23	Telephone number: +46761107007
24	Total word count: 4962
25	

26 ABSTRACT

27 BACKGROUND

28 Menopausal vasomotor symptoms (VMS) have been associated with subclinical and manifest

29 atherosclerotic cardiovascular disease (ASCVD) but have not been studied in relation to

30 image-detected coronary atherosclerosis. We assessed the association between VMS and

subclinical ASCVD in peri- and postmenopausal women, considering a wide range of

32 cardiovascular related risk factors that could potentially influence the relationship.

33 METHODS

34 This cross-sectional population-based study was conducted on a subset of participants from

the Swedish CArdioPulmonary BioImage Study (SCAPIS), including women 50-65 years of

age. The women underwent comprehensive cardiovascular assessments and completed an

37 extensive questionnaire, which included questions about current and previous menopause-

related symptoms. VMS was assessed on a 4-point scale and analyzed in relation to

39 subclinical ASCVD, detected via coronary computed tomography angiography (CCTA),

40 coronary artery calcium score (CACS) and carotid ultrasound using logistic regression

41 analyses.

42 RESULTS

43 Of 2995 women included, 14.2% reported previous or on-going severe VMS (n=425), 18.1%

44 moderate VMS (n=543), and 67.7% no or mild VMS (n=2027). Women who had ever

45 experienced severe VMS, but not those with ever moderate VMS, had higher prevalence of

46 CCTA-detected coronary atherosclerosis (34.1 vs 27.8%, p=0.017), but not segmental

47 involvement score (SIS) >3 (4.5 vs 5.1%, p=0.332), CACS>100 (5.8 vs 6.8%, p=0.166) or

any carotid plaque (47.6% vs 46.6%, p=249) than women with never or ever mild VMS.

49 Using the same reference, ever severe but not moderate VMS was significantly associated

50 with CCTA-detected coronary atherosclerosis, odds ratio (OR) after multivariable adjustment

51 1.33, 95% CI 1.02–1.72. This association was only present for durations of severe VMS of

52 more than 5 years (multivariable adjusted OR 1.53 95% CI 1.09-2.14) or when the onset of

severe VMS occurred before menopause (multivariable adjusted OR 1.60 95% CI 1.06-2.42).

54 Additional adjustment for menopausal hormone therapy strengthened the associations

55 whereas additional adjustment for physical activity did not. No significant association with

56 SIS>3, CACS>100, nor with any carotid plaque was observed.

57 CONCLUSIONS

- 58 Previous or on-going severe but not moderate VMS were significantly associated with CCTA-
- 59 detected coronary atherosclerosis, independent of a broad range of cardiovascular risk factors.
- 60 No corresponding associations was observed for SIS>3, CACS>100 or carotid
- 61 atherosclerosis.
- 62

64 KEY WORDS:

- 65 Vasomotor symptoms; Menopause; Menopausal symptoms; Subclinical
- 66 atherosclerosis; Cardiovascular disease.

68 Abbreviations

- 69 ASCVD atherosclerotic cardiovascular disease
- 70 CAC coronary artery calcium
- 71 CACS coronary artery calcium score
- 72 CCTA coronary computed tomography angiography
- 73 C-IMT carotid intima media thickness
- 74 CT computed tomography
- 75 CVD cardiovascular disease
- 76 MHT menopausal hormone therapy
- 77 MVPA moderate to vigorous physical activity
- 78 SCAPIS Swedish CArdioPulmonary bioImage Study
- 79 SIS segment involvement score
- 80 SWH Study of Women's health
- 81 VMS vasomotor symptoms

82 Clinical Perspective:

• What is new?

84	0	Previous or ongoing severe vasomotor symptoms were, independent of a wide
85		range of cardiovascular risk factors, significantly associated with coronary
86		atherosclerosis identified by coronary computed tomography angiography
87		screening of the general population, aged 50-65 years.
88	0	The association was limited to women with a duration of severe vasomotor
89		symptoms of more than five years or whose severe vasomotor symptoms began
90		before menopause onset.
91	What	are the clinical implications?
92	0	Our results reflect a need for extra vigilance regarding cardiovascular risk factors
93		in women suffering from severe vasomotor symptoms.

94 1. Introduction

Atherosclerotic cardiovascular disease (ASCVD) is a major cause of mortality and morbidity
in women (1), to which female reproductive factors appear to contribute (2, 3). To improve
primary prevention strategies for ASCVD in women, there is a need for greater understanding

98 of female specific risk factors that can be the focus of targeted preventive efforts (4).

99 Susceptibility to ASCVD in women increases considerably after menopause (5, 6), when

100 estrogen levels decline sharply (7) and the prevalence of cardiovascular risk factors increases

101 (8, 9). The decline in estrogen levels is often accompanied by climacteric symptoms (7), such

as hot flushes and night sweats, known as vasomotor symptoms (VMS), affecting

approximately 80-97% of women (10, 11) with varying frequency and severity (10, 12). The

104 VMS duration is usually between 5 and 7 years (11, 13), but with an early onset the duration

appears to be longer (10). There is an association between VMS and sleep-related problems,

depressive symptoms, and a generally impaired quality of life (13, 14), especially among

107 women with long VMS duration (13).

108 The most effective VMS treatment is menopausal hormone therapy (MHT) with either

109 estrogen alone or in combination with gestagen. The prescription rate, however, has been

relatively low for the past two decades, mainly due to cardiovascular safety concerns (15).

111 Whereas endogenous estrogen appears to counteract the early atherosclerosis process (16), the

112 menopausal transition is linked to progressive changes in tissue estrogen receptor

113 characteristic (17). Consequently, the response to exogenously administered estrogen may

differ depending on when treatment is initiated (18). Current guidelines support MHT for

bothersome VMS in women within 10 years since menopause or ≤ 60 years of age at treatment

initiation (19). Another proposed therapy for treatment of VMS is physical activity (20), but

as the evidence is ambiguous it is not included in prevailing VMS treatment guidelines.

118 Women with VMS appear to have an unfavorable cardiovascular risk profile and previous

119 observational studies have found associations with cardiovascular risk factors such as

120 hypertension, hypercholesterolemia, and overweight/obesity (21). Studies on measures of

121 subclinical ASCVD have yielded discrepant results. Associations with carotid intima media

thickness (C-IMT) and aortic calcification have been demonstrated (21-24) but not with

123 coronary artery calcium (CAC) (21). In prospective studies, associations between VMS and

124 major adverse cardiac events (MACE) have been observed (25, 26). However, no distinct

mechanism has yet been identified and it is still unclear whether VMS constitutes an

126 independent risk factor for developing ASCVD.

- 127 To gain a better understanding of how VMS are associated with ASCVD, population-based
- studies are needed, allowing for comprehensive adjustments. Using subclinical outcome
- 129 measures has the advantage of investigating associations with early-stage ASCVD when the
- 130 opportunities for preventive interventions are greatest. Previous research addressing a
- 131 possible association between VMS and subclinical ASCVD has been limited to the use of
- 132 CAC and carotid ultrasound measurements as outcomes. The current study adds coronary
- 133 computed tomography angiography (CCTA), a low dose imaging technique measuring
- 134 coronary atherosclerosis with the ability to identify both the anatomical distribution and the
- 135 characteristics of coronary atherosclerosis and plaques (27).
- 136 The current study aimed to assess associations between VMS and subclinical ASCVD
- 137 detected through CCTA, CACS or carotid ultrasound, and to determine if potentially observed
- 138 associations are modified by cardiovascular related risk factors.
- 139 2. Material & Methods

140 2.1. Study design and population

141 This is a sub-study of the Swedish CArdioPulmonary BioImage Study (SCAPIS) - a

142 multicenter population-based observational study aimed at improving prediction and

143 prevention of CVD (26). The SCAPIS protocol, described in detail elsewhere (26), was

144 consistent for all centers and included collection of data through a comprehensive

145 questionnaire, anthropometry, electrocardiogram (ECG), blood pressure, accelerometer

146 measurements of physical activity, blood sampling, and extensive cardiovascular imaging.

147 Female study participants at two of the SCAPIS centers (Stockholm and Linköping) were

148 invited to participate in the sub-study Survey on Women's Health (SWH), requiring

149 completion of an additional questionnaire including questions about menopausal status, age at

- 150 menstrual cessation, menopausal symptoms including VMS, and the use of MHT and
- 151 naturally derived compounds. The questionnaire was first tested in a small pilot study and
- some adjustments for greater clarity were made. Of the women invited to the SWH, 98% (n =
- 153 5043) agreed to participate. Among those, 578 women gave no information about menopausal
- 154 status and were therefore not considered. The current study also has the following exclusion
- criteria: 1) being premenopausal (i.e., regular menses during the last year), 2) loss of

menstruation due to other causes than natural menopause (hormonal treatments, surgical
menopause, excessive exercising or dietary restrictions, pregnancy or breastfeeding), and 3)
missing data on VMS.

The data collection took place between October 2015 and March 2018 in Stockholm and between October 2015 and June 2018 in Linköping. Data from SCAPIS were linked through each individual's unique personal identification number to the National Patient Register and the National Prescribed Drug Register, maintained by the National Board of Health and

163 Welfare, in order to obtain information about medical history.

164

2.2. Menopause and vasomotor symptoms

165 Menopausal status was defined as perimenopausal (<12 months amenorrhea), early

166 postmenopausal (\geq 12-36 months amenorrhea), late postmenopausal (\geq 36-72 months

amenorrhea) or very late postmenopausal (>72 months amenorrhea).

168

The SWH asked whether the women had ongoing or previous VMS, and if so to what degree 169 170 and with what duration. Information on age at the start of VMS was requested. In case of 171 MHT, the instruction was to report VMS as they were before medication initiation. A four-172 point intensity scale was used, in accordance with the structure of "The Greene climacteric scale" (28), an established questionnaire to identify VMS: 1) never, 2) mild, 3) moderate, or 173 174 4) severe VMS. Herein, ongoing or previous exposure to VMS, regardless of intensity, are collectively referred to as 'never', 'mild', 'moderate' or 'severe' VMS. The questionnaire 175 176 included a question on frequency of VMS in the last two weeks, with five predefined response options: 1) no symptoms, 2) occasionally, 3) a few times per week, 4) once a day, and 5) 177 several times per day. Women also reported on whether they had other menopausal symptoms 178 or ever used naturally derived herbal medicine as treatment (e.g., phytoestrogens) for VMS. 179

180

2.3. Coronary and carotid atherosclerosis measures

181 CCTA data were collected using multi-slice CT scanner (Siemens, Somatom Definition Flash,

182 Siemens Healthineers, Erlangen, Germany). Identical software and hardware were used at

both study sites. Details of image collection, processing, analyses, reconstruction, reading,

and scoring are published elsewhere (29). Atherosclerosis was reported in 18 segments (30),

185 with findings from the most clinically relevant segments (1 through 3, 5 through 7, 9, 11

through 13, and 17) mandatory to report. Coronary artery status was classified as no

187 atherosclerosis, any atherosclerosis, nonsignificant (i.e., 1% to 49%) stenosis, significant (i.e.,

188 \geq 50%) stenosis, missing segment or not assessable due to calcium blooming or technical

189 failure. The coronary segmental involvement score (SIS) was calculated by adding the

segments with present atherosclerosis and a score >3 indicates more widespread

191 atherosclerosis.

192 The CAC images were acquired using ECG-gated non-contrast CT at 120 kV and CAC score

193 (CACS) was calculated after summing the calcium content in each coronary artery according

to Agaston (31). In regression analyses, CACS was dichotomized into 0-100 or >100 Agaston

195 units.

196 The carotid arteries were assessed bilaterally for atherosclerotic plaques in the common

197 carotid artery, bulb, and the internal carotid artery. Results were categorized as no, unilateral,

198 or bilateral plaques. Siemens Acuson S2000 ultrasound scanner equipped with a 9L4 linear

199 transducer (Siemens Healthineers, Erlangen, Germany) was used according to a standardized

200 protocol. The definition of plaques is described in more detail elsewhere (32, 33).

The primary measures of subclinical ASCVD in the present study were 1) any coronary atherosclerosis, 2) SIS >3, 3) CACS >100, and 4) any carotid plaque.

203 2.4. Covariates

204 The procedures behind the physical examinations, anthropometry and the collection and analyzing of blood samples have previously been described (29). Based on questionnaire data, 205 206 binary variables for educational level, country of birth, employment status, financial strain, quality of sleep, continuous stress, depressive symptoms, and specific medical diagnoses were 207 208 created. Details about how all variables were created are given in supplement. The 209 participants were categorized as current, previous, or never smokers. Among smokers, the 210 sum of cigarette pack-years was calculated. Data on family history of myocardial infarction (MI) and stroke, respectively, and alcohol habits were obtained from the questionnaire and 211 212 treated as binary variables (see supplement).

Accelerometry was used to measure physical activity and sedentary time. Study participants
wore a tri-axial accelerometer (ActiGraph LCC, Pensacola) on their right hip during waking
hours for seven consecutive days. The ActiLife v.6.13.3 software was used to set up,

download and process the data (34). The processed data were registered as counts per minute

217 (cpm), with higher cpm indicating more intense physical activity. Physical activity intensities

were categorized into 1); "Sedentary"; 0 and 199 cpm 2) "Light physical activity"; 200-2689

cpm and 3) 'Moderate to vigorous (MVPA)'; ≥2690 cpm, based on percentage of all wear

time, in accordance with previous studies (34). The variables, MVPA and sedentary, were

used descriptively for this study and MVPA was used in the regression models.

Women who reported use or past use of systemic prescription MHT, either in the form of oral pills, transdermal patches or transdermal gels and irrespective of indication, were considered as ever users of MHT. Subsequently, a categorical variable was created considering duration of use: 1) never user, 2) 1-4 years, and 3) \geq 5 years. For sensitivity analyses, a subcategory of women who initiated MHT >6 years since menopause was created.

227 2.5. Statistical analysis

Mean and standard deviation (SD) or median with 25th and 75th percentiles were calculated 228 for continuous variables as appropriate, depending on data being normally distributed or not. 229 230 Data distribution also determined whether independent T-tests or Mann-Whitney U tests were used to assess statistical significance in comparisons across groups; the Chi² test was used for 231 232 categorical variables. Multivariate logistic regression models were performed to assess associations between VMS and subclinical ASCVD, with results presented as odds ratios 233 (OR) with 95 % confidence intervals (CI). Women who never had experienced VMS and 234 235 women with mild VMS were combined (herein referred to as the never/mild group) and 236 served as the reference category in all analyses, in comparison with the moderate and severe groups, respectively. Women with a history of ischemic heart disease (definition given in 237 supplement), percutaneous coronary intervention (PCI) and/or coronary artery bypass grafting 238 (CABG) were excluded in analyses of associations between VMS and coronary 239 240 atherosclerosis and CACS, and women with a history of ischemic stroke were excluded when analyzing associations with carotid plaques (Figure 1). Crude univariate models, and five 241 multivariate models adjusted for different sets of variables were used. Model 1 included age 242 243 at time of study inclusion and site. Model 2 included model 1 and a block of socioeconomic, 244 demographic, lifestyle related and clinical cardiovascular risk factors: educational level, 245 country of birth, menopausal status, systolic blood pressure, waist circumference, low density 246 lipoprotein (LDL) cholesterol, triglycerides, diabetes mellitus, medically treated hyperlipidemia, medically treated hypertension, and smoking status. Model 3 included model 247 2 and a block of additional factors previously shown to be more prevalent among women with 248 249 VMS and suggested to associate with ASCVD: continuous stress, quality of sleep, depression, 250 and sleep apnea. Model 4 and Model 5 included model 3 and in addition MVPA and MHT, 251 respectively, to explore any change in OR point estimates.

- 252 To investigate whether duration of VMS had a bearing on the studied associations between
- 253 VMS and subclinical ASCVD, we created a binary variable distinguishing longer and shorter
- duration. Since there is no established limit to make such distinction, we chose a cut-off
- corresponding to the median VMS duration in the study sample. Then a variable was
- created with the following categories: 1) never/mild (reference), 2) moderate VMS \leq 5 years,
- 257 3) moderate VMS \geq 5 years, 4) severe VMS \leq 5 years, and 5) severe VMS \geq 5 years.
- 258 Correspondingly, we investigated whether the timing of the start of the VMS had a bearing on
- the studied association between VMS and ASCVD. The variable created had the following
- categories: 1) never/mild VMS (reference), 2) moderate VMS staring before menopause, 3)
- 261 moderate VMS starting after menopause, 4) severe VMS starting before menopause, and 5)
- severe VMS starting after menopause.
- 263 In supplementary analyses of VMS intensity in relation to coronary atherosclerosis, women
- 264 with mild VMS served as the reference category, whereas women who had never experienced
- 265 VMS constituted a separate category. Supplementary analyses were also performed to assess
- 266 VMS in relation to CACS >0 as well as bilateral and unilateral carotid plaques. Finally, a
- sensitivity analysis was performed excluding women with late start (>6 years) of MHT. Self-
- 268 reported physical activity was also considered instead of the objectively measured MVPA in a
- 269 separate sensitivity analysis.
- P-values <0.05 were considered to indicate statistical significance. All analyses were
 performed with SPSS v.28.0 (IBM, Portsmouth, UK).
- 3. Ethical considerations
- This study was conducted in accordance with the Declaration of Helsinki, with oral and
 written informed consent before participation. The SCAPIS study as well as the SWH was
- approved by the Swedish Ethical Review Authority (reference numbers: 2010-228-31M,
- 276 2015-246/32, and 2020-03101). SN and KL had full access to all the data in the study and
- take responsibility for its integrity and the data analysis. The authors declare that all
- supporting data are available within the article.

4. Results

280 4.1 Descriptive characteristics

- Among the randomly selected Swedish men and women invited to participate in SCAPIS,
- 282 30,154 individuals were recruited (50.3%). The participation rate was similar between sexes

and ages (27). The mean age of the 4465 participants in the SWH population was 57.4 years;

82.6% were postmenopausal and 8.2% perimenopausal (characteristics presented in

285 Supplementary Tables 1-3). After excluding participants according to the pre-specified

criteria, 2995 women remained and constituted the study population (Figure 1). Of these,

43.3% reported mild, 18.1% moderate, and 14.2% severe VMS whereas 24.4% had never

experienced VMS. Women in the severe group were more likely to be postmenopausal (93.4

vs 88.9%, p <0.01), and they experienced other menopausal symptoms (42.1 vs 24.3%,

p<0.01) and used herbal medicines (e.g., phytoestrogens) (20.4 vs 5.5%, p<0.01) to a greater

extent than women with never/mild VMS. Characteristics of the study population by VMS

intensity are presented in Tables 1 and 2.

293 VMS occurred significantly earlier in women who reported ever severe VMS, than in those

who reported never/mild VMS (mean age 49.4 vs 50.5, p<0.01). The duration of VMS was

significantly longer in both the severe VMS group (median 6 years) and the moderate VMS

296 group (median 5 years) than in the never/mild group (median 4 years; p < 0.01). There was a

significantly higher frequency of daily VMS the past two weeks in the severe (68.6%) and

moderate (62.3%) group than in the never/mild group (29.1%) (Table 2).

Among women in the study population with current or previous MHT use, 91.6% started their

treatment within 6 years after menopause and the median duration of use was 4 years. Women

301 with ever severe or moderate VMS were more likely to have used MHT compared to the

never/mild group (50.3 vs 10.9% and 31.7 vs. 10.9%; p<0.01). In women with severe VMS,

303 24.9% had used MHT for \geq 5 years, while the corresponding proportions in the moderate and

304 mild VMS group were 12.2% and 3.5% (Table 2).

305 Women in the severe VMS group were more often born outside Sweden, had lower education,

and suffered from financial strain the last year more than the never/mild VMS group. Further,

they reported worse sleep habits and more continuous stress the last 5 years, were more often

308 overweight, sedentary, past smokers and had smoked more pack years of cigarettes.

Approximately 30% in this group fulfilled criteria for depression compared to 20% in the

310 never/mild VMS group. There were no differences between VMS groups in MVPA, blood

311 pressure or cardiometabolic biomarkers, except triglycerides, which were higher in the severe

312 VMS group (p<0.01)(Table 1).

313 The prevalence of any CCTA-detected coronary atherosclerosis was higher in the severe

VMS group than in the never/mild group (34.1 vs. 27.8%, p = 0.017). Similarly, CACS >0

was more prevalent in the severe VMS group than in the never/mild group (34.4 vs 29.3%, p

- = 0.014). For moderate VMS there were no corresponding differences compared to the
- never/mild group. The prevalence of SIS >3 and CACS >100 did not differ significantly
- between groups. The prevalence of bilateral carotid plaques was higher in the severe group
- compared to the never/mild group (21.9 vs 17.5%, p = 0.032), but for the moderate group the
- 320 corresponding difference was not observed (19.1 vs. 17.5%, p = 0.398). The prevalence of
- 321 unilateral carotid plaques did not differ significantly between groups (Table 3).
- 322 In supplemental analyses, the group who never had any VMS was compared to the group
- 323 reporting mild VMS (Supplementary Tables 5-7). Women who never experienced VMS were
- significantly older, more often born outside Sweden, lower educated, unoccupied, and
- suffered from financial strain the last year more often than the group with mild VMS. They
- were also more frequently obese, and had on average a greater waist circumference, higher
- 327 blood pressure and a worse cardiometabolic biomarker risk profile compared to women with
- 328 ever mild VMS. The prevalence of ischemic stroke, hypertension, and diabetes mellitus was
- 329 also higher in this group. In addition, they had higher CACS and a more widespread coronary
- atherosclerosis than women with mild VMS.
- The proportion of missing data was <8% for the variables used in the regression models. The frequency of missing data for all variables is given in the Supplementary Table 4.
- 4.2 VMS in relation to subclinical ASCVD
- 334 The results from the multivariable regression models with subclinical ASCVD are presented
- in Supplementary Table 8 and illustrated in Figure 2. Severe VMS were significantly
- associated with coronary atherosclerosis (crude OR 1.36, 95% CI 1.08 1.72). The
- association was slightly weaker after the multivariable adjustment in model 3, OR 1.33 (95%
- 338 CI 1.02-1.72) whereas additional adjustment for MHT (model 5) yielded a slightly stronger
- association, OR 1.41 (95% CI 1.06-1.87). In model 5, when excluding women with start of
- 340 MHT > 6 years after menopause, the result remained similar (OR 1.44, 95% CI 1.08 1.93)
- 341 (Supplementary Table 9). Moderate VMS was not significantly associated with coronary
- 342 atherosclerosis in any of the models.
- 343 If severe VMS lasted >5 years, the association with coronary atherosclerosis was more
- pronounced, crude OR 1.70, 95% CI 1.26 2.30 (Figure 2 and Supplementary Table 10). This
- association was weakened but still significant in model 1, (OR 1.48, 95% CI 1.09 2.01), and
- similar in model 2 (OR 1.49, 95% CI 1.07 1.97), model 3, (OR 1.53, 95% CI 1.09 2.14)

- and model 4 (OR 1.50, 95% CI 1.07 2.11). In model 5, where MHT was added, the
- association was strengthened (OR 1.67, 95% CI 1.16 2.40) (Figure 2). For severe VMS with
- shorter duration (\leq 5 years), the association with coronary atherosclerosis was not significant
- 350 (Supplementary Table 10). For moderate VMS, no effect of symptom duration was observed
- in relation to coronary atherosclerosis (Supplementary Table 10). For severe VMS that started
- before menopause, but not for VMS that started after menopause, a significant association
- 353 with coronary atherosclerosis was observed that persisted after multivariable adjustments,
- 354 model 3 OR 1.60 (95% CI 1.06-2.42) and model 5 OR 1.69 (95% CI 1.10 2.60)
- 355 (Supplementary Table 11).
- Neither moderate nor severe VMS were significantly associated with CACS >100,
- 357 widespread coronary disease (SIS >3) or any carotid plaque (Supplementary Table 8, Figure
- 2). In supplementary analyses, severe VMS were significantly associated with CACS >0 in
- the crude model but not after multivariable adjustments (Supplementary Table 12). Severe
- 360 VMS were significantly associated with bilateral carotid plaques in crude analyses and
- 361 borderline significant after multivariable adjustments (Supplementary Table 13). For
- 362 unilateral plaque, no significant association was observed.

363 5. Discussion

In this nation-wide population-based study, we found that ongoing or previous severe, but not moderate, VMS were significantly associated with coronary atherosclerosis detected with CCTA, independent of a wide range of lifestyle, socioeconomic and clinical cardiovascular risk factors. To our knowledge this is the first time CCTA data have been used assessing the association between VMS and subclinical ASCVD.

369 In keeping with a previous study (13), women who experienced severe VMS had the earliest 370 onset and longest duration of VMS. Arguably, VMS duration could have bearing on the 371 strength of the association to coronary atherosclerosis. To the best of our knowledge, this has 372 not been studied previously, and interestingly, our results show that severe VMS lasting >5 373 years were significantly associated with coronary atherosclerosis, whereas no corresponding 374 association was observed for shorter durations. Moderate VMS, however, was not associated 375 with coronary atherosclerosis regardless duration. We also found that pre-menopausal but not 376 post-menopausal onset of severe VMS was associated with coronary atherosclerosis. These findings agree with the American Study of Women's Health Across the Nation, which 377 reported associations between frequent VMS persistence over time and incident CVD (25). 378

379 The findings are also consistent with results from the Women's Ischemia Syndrome

380 Evaluation (WISE) that show associations between early onset VMS and reduced endothelial

function and CVD mortality (35). However, results from a study that pooled data from six

different prospective studies show that both pre-menopausal and post-menopausal onset of

383 VMS are associated with incident CVD (26).

384 The persisting association between severe VMS and coronary atherosclerosis after adjustment 385 for conditions known to be prevalent in women with VMS, such as sleep disturbances and 386 depression (13, 14), is on the one hand surprising as VMS could have a negative impact on 387 lifestyle and sleep quality, which in turn could increase the risk of ASCVD. On the other 388 hand, our results are consistent with several previous studies of VMS in relation to subclinical 389 CVD and incident manifest CVD where no substantial impact on the results were observed 390 when adjusting for such covariates (22-26). Although it cannot be ruled out that severe VMS 391 is merely a marker of an unfavorable cardiovascular risk profile, our findings of an 392 independent relationship between severe VMS and coronary atherosclerosis could indicate an 393 unknown underlying pathophysiological mechanism, either in the initiation or the progression 394 of the atherosclerotic process in midlife women. Further research is required to elucidate 395 mechanisms by which VMS may exert a deleterious effect on the coronary arteries, but we 396 can speculate that women with long-term severe VMS or whose severe VMS started early 397 may have increased sensitivity to hormonal fluctuations, which in turn may contribute to 398 atherosclerotic development via autonomic neurovascular dysregulation (36). Thus, these 399 women may in general have an underlying adverse vascular reactivity manifested during the 400 menopausal transition. Effects could perhaps be related to an over-reactivity of the 401 sympathetic nervous system, with inhibition of cardiac vagal control (37), or to changes in the 402 hypothalamic-pituitary-adrenal (HPA) axis associated with variable cortisol concentrations 403 (38, 39). Furthermore, because the fast withdrawal of estrogen during menopausal transition 404 rather than the absolute plasma level may be connected to an instability in the 405 thermoregulatory center in hypothalamus (40), it seems reasonable that increased central 406 thermoregulatory sensitivity or hampered adaptation capacity may indirectly be related to a 407 heightened central sympathetic tone, resulting in an over-activity of the sympathetic nervous 408 system (40, 41).

409 The analyses of VMS in relation to the other subclinical ASCVD measurements - CACS

100, SIS >3 and any carotid plaque - showed no significant associations. To improve

411 comparison to previous study results, we added analyses on VMS in relation to CACS >0.

412 Still, we observed no significant associations after multiple adjustments (Supplementary 413 Table 12). These findings are in line with most previous studies on VMS in relation to CACS 414 and/or carotid atherosclerosis(21), with some exceptions (22, 23). CCTA is a diagnostical and 415 non-invasive angiographic method able to detect coronary artery disease (CAD), compared to CAC that rather predicts risk for future manifest CVD events (42). While CACS reflects the 416 sum of coronary calcifications, CCTA can detect calcified as well as non-calcified plaques, 417 418 degree of plaque stenosis, and extended plaque features such as plaque stability and 419 anatomical distribution (43). Thus, VMS might be associated to early coronary 420 atherosclerosis, already before the development of calcified plaques, which might explain the 421 observation of a strong and independent association for CCTA-detected coronary atherosclerosis but not with coronary calcification. Since SIS >3 was uncommon in the 422 included age group, we might lack statistical power to detect significant differences and thus 423 424 cannot rule out true associations. Although the atherogenesis appears to be similar for both coronary and carotid plaques (44), the lack of significant associations between severe VMS 425 426 and any carotid plaque could relate to a different pathophysiology behind the development of 427 coronary and carotid atherosclerosis. However, in the supplementary analyses severe VMS 428 were borderline significantly associated with bilateral carotid plaque, which compared to 429 unilateral carotid disease has been shown so be a better predictor of the 5-year risk of 430 coronary death (45). Although this may be a spurious finding, there is a possibility that 431 unilateral carotid atherosclerosis is rather caused by anatomical and hemodynamic factors, 432 while bilateral carotid plaques reflect a more extensive atherosclerotic disease with systemic 433 factors giving rise to its development (45).

434 For analyzes of VMS in relation to subclinical ASCVD, the choice of "reference group" is not 435 obvious and varying definitions of "bothersome" symptoms makes comparisons between studies challenging. In previous studies, women without VMS have usually constituted the 436 437 reference group. We found that women who never experienced VMS had significantly more 438 cardiovascular risk factors and coronary atherosclerosis than women with mild VMS, a 439 finding consistent with the results from the WISE study, which observed an increased CVD 440 mortality in this group compared with women with late-onset VMS (35). Thus, women 441 without VMS may not always have the lowest risk of developing ASCVD and thus our 442 reference category also included women who reported mild VMS, which constituted the 443 largest group in our study population (43.3%) (Supplementary Table 14).

444 Women with severe VMS performed MVPA to a similar extent as women with no or mild 445 VMS. Neither did self-reported level of physical activity differ significantly between the 446 groups. Hence, we found no indication that physical activity would mitigate a potential 447 detrimental effect of VMS on the coronary arteries. This somewhat contradicts previous 448 results showing that physically active as compared to sedentary postmenopausal women 449 report less VMS (20). Although the current study was not designed to study treatment effects, 450 it is relevant to note that the association between >5 years of VMS and coronary 451 atherosclerosis became stronger when adjusting for MHT, as this could possibly signal a 452 mitigating effect. However, this result must be interpreted with caution due to bias related to 453 confounding by indication. Contraindications for prescribing MHT have since the WHI-study 454 (46) included a history of cardiovascular disease, which means a selection of cardiovascular 455 healthier women prescribed MHT. On the other hand, VMS severity could also influence 456 whether the woman is treated with MHT or not, which, under the assumption that severe VMS affect the development of subclinical atherosclerosis, means a selection against 457 cardiovascular less healthy women prescribed MHT. 458

459 There are several limitations to our study. Firstly, the cross-sectional observational study 460 design limits any causal conclusions to be drawn since we do not know when VMS appeared 461 in relation to the atherosclerosis development. Secondly, the results may not be generalizable 462 to other geographical regions, ethnicities and age-groups since the definitions and prevalence 463 of VMS differ (10, 13). Thirdly, the assessment of VMS may be subject to recall bias, given 464 that up to 10-15 years could have passed since the study participants experienced their 465 symptoms. However, it is likely that such recall bias would be non-differential because the 466 women were not aware of their measures of subclinical coronary atherosclerosis or other 467 cardiovascular risk assessments when they completed the questionnaire. In that case, this would have a weakening effect on our results. 468

469

6. Conclusions

470 Ongoing or previous severe VMS, with >5 years duration or beginning before menopause,

were significantly associated with subclinical CCTA-detected coronary atherosclerosis, 471

independent of a wide range of socioeconomic, demographic, lifestyle-related and clinical 472

473 cardiovascular risk factors. No corresponding associations were observed for SIS >3, CACS

- 474 >100 or any carotid plaque. Further research is required to establish a possible causal
- 475 relationship between severe VMS and coronary atherosclerosis, as well as the

- 476 pathophysiological mechanism behind such association. However, our findings support a
- 477 more consistent implementation of preventive cardiovascular strategies in gynecological care,
- targeting women with severe VMS which may be a marker of poor or ongoing deterioration
- 479 of cardiovascular health. Here is a window of opportunity for preventing cardiovascular
- 480 disease in midlife women, as severe VMS increase the propensity to seek medical advice.
- 481 7. Acknowledgements
- 482 We would like to thank Professor and MD Mats Hammar for his support in conceptualization
- 483 of the SWH questionnaire. In addition, authors would like to thank Max Vikström
- 484 (Karolinska Institutet, Unit of Cardiovascular and Nutritional Epidemiology, Institute of
- 485 Environmental Medicine, Stockholm, Sweden) for his assistance and support with the
- 486 statistical analyses.

488 Funding

- 489 The main funding body of The Swedish CArdioPulmonary bioImage Study (SCAPIS) is the
- 490 Swedish Heart-Lung Foundation. The study is also funded by the Knut and Alice Wallenberg
- 491 Foundation, the Swedish Research Council and VINNOVA (Sweden's Innovation agency)
- 492 the University of Gothenburg and Sahlgrenska University Hospital, Karolinska Institutet and
- 493 Stockholm County council, Linköping University and University Hospital, Lund University
- and Skåne University Hospital, Umeå University and University Hospital, Uppsala University
- and University Hospital. The current study was supported by grants from the Swedish Heart-
- 496 Lung foundation (grant number 20220190) to KL and grants from the County Council of
- 497 Östergötland to ACSH.
- 498 Disclosures
- 499 There are no financial conflicts of interest to disclose.
- 500 Author contributions
- 501 Sigrid Nilsson contributed to investigation, validation, visualisation, methodology, formal
- analysis, writing the original draft, reviewing, and editing the manuscript.
- 503 Angelika Qvick contributed to investigation, validation, visualisation, methodology, writing
- the original draft, reviewing, and editing the manuscript.
- 505 Moa Henriksson contributed to data curation, reviewing, and editing the manuscript.
- 506 Anna-Clara Spetz Holm contributed to supervision, conceptualisation, project administration,
- 507 validation, investigation, reviewing and editing the manuscript.
- 508 Sofia Sederholm Lawesson contributed to supervision, validation, investigation,
- 509 methodology, reviewing and editing the manuscript.
- 510 Karin Leander contributed to supervision, conceptualisation, project administration, data
- 511 curation, methodology, validation, investigation, reviewing and editing the manuscript, and
- 512 funding acquisition.

513 ORCID-ID

- 514 SN: <u>sigrid.nilsson@liu.se</u>, 0000-0002-9604-8062
- 515 AQ: angelika.qvick@ki.se, 0000-0003-4149-5399
- 516 MH: moa.a.henriksson@liu.se, 0000-0003-2592-1140
- 517 ACSH: anna-clara.spetz.holm@liu.se, 0000-0002-0268-2901

- 518 SSL: <u>sofia.lawesson@liu.se</u>, 0000-0002-4776-0870
- 519 KL: <u>Karin.Leander@ki.se</u>, 0000-0002-1404-9222
- 520 Supplemental Material
- 521 Supplemental methods
- 522 Supplemental tables 1-14
- 523 References (47-50)
- 524 Figure legends
- 525 Figure 1. Flowchart for selection of the study population (n=2995)
- 526 SCAPIS = Swedish CArdioPulmonary bioImage Study; ASCVD = Atherosclerotic
- 527 cardiovascular disease; SWH = Study of Women's health; VMS = Vasomotor symptoms;
- 528 CCTA = Coronary computed tomography angiography; CAC = Coronary artery calcium; IHD
- 529 = Ischemic heart disease; PCI = Percutaneous coronary intervention; CABG = Coronary

artery bypass graft. * Hormonal treatments, surgical menopause, excessive exercising ordietary restrictions, pregnancy or breastfeeding.

- Figure 2. Vasomotor intensity and duration in relation to occurrence of subclinical ASCVD.
- 534 The panels show results different subclinical ASCVD measures: Panel a) Any coronary
- atherosclerosis, Panel b) SIS >3, Panel c) CACS >100, and Panel d) any carotid plaque. All
- 536 statistical comparisons have the never/mild group as reference. CRUDE: no adjustments;
- 537 Model 1: age at time of study inclusion + site; Model 2: model 1 + highest degree of
- education, country of birth, systolic blood pressure, waist circumference, low density
- 539 lipoprotein, triglycerides, diabetes mellitus, hyperlipidemia, hypertension, smoking status,
- and menopausal status; Model 3: model 2 + experienced stress, sleep habits, depression,
- and sleep apnea; Model 4: model 3 + moderate to vigorous physical activity; Model 5: model
- 542 3 + menopausal hormone therapy. SCAPIS = Swedish CArdioPulmonary bioImage Study;
- 543 VMS = Vasomotor symptoms. SCAPIS = Swedish CArdioPulmonary bioImage Study;
- 544 ASCVD = Atherosclerotic cardiovascular disease; VMS = Vasomotor symptoms; Segmental 545 involvement score; CACS = Coronary artery calcium score.

547 References

Wenger NK, Lloyd-Jones DM, Elkind MSV, Fonarow GC, Warner JJ, Alger HM, 548 1. 549 et al. Call to Action for Cardiovascular Disease in Women: Epidemiology, Awareness, 550 Access, and Delivery of Equitable Health Care: A Presidential Advisory From the American 551 Heart Association. Circulation. 2022;145(23):e1059-e71. 552 Maas A, Rosano G, Cifkova R, Chieffo A, van Dijken D, Hamoda H, et al. 2. 553 Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European cardiologists, 554 555 gynaecologists, and endocrinologists. Eur Heart J. 2021;42(10):967-84. Sederholm Lawesson S, Swahn E, Pihlsgard M, Andersson T, Angeras O, 556 3. 557 Bacsovics Brolin E, et al. Association Between History of Adverse Pregnancy Outcomes and Coronary Artery Disease Assessed by Coronary Computed Tomography Angiography. 558 559 JAMA. 2023;329(5):393-404. 560 4. El Khoudary SR, Aggarwal B, Beckie TM, Hodis HN, Johnson AE, Langer RD, 561 et al. Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of 562 Early Prevention: A Scientific Statement From the American Heart Association. Circulation. 563 2020;142(25):e506-e32. Garcia M, Mulvagh SL, Merz CN, Buring JE, Manson JE. Cardiovascular 564 5. 565 Disease in Women: Clinical Perspectives. Circ Res. 2016;118(8):1273-93. 566 Matthews KA, Crawford SL, Chae CU, Everson-Rose SA, Sowers MF, 6. 567 Sternfeld B, et al. Are changes in cardiovascular disease risk factors in midlife women due to 568 chronological aging or to the menopausal transition? J Am Coll Cardiol. 2009;54(25):2366-569 73. 570 7. Nelson HD. Menopause. Lancet. 2008;371(9614):760-70. 571 8. Collins P, Rosano G, Casey C, Daly C, Gambacciani M, Hadji P, et al. 572 Management of cardiovascular risk in the peri-menopausal woman: a consensus statement 573 of European cardiologists and gynaecologists. Eur Heart J. 2007;28(16):2028-40. 574 9. Gast GC, Grobbee DE, Pop VJ, Keyzer JJ, Wijnands-van Gent CJ, Samsioe 575 GN, et al. Menopausal complaints are associated with cardiovascular risk factors. 576 Hypertension. 2008;51(6):1492-8. 577 10. Yu Q, Chae HD, Hsiao SM, Xie J, Blogg M, Sumarsono B, et al. Prevalence, 578 severity, and associated factors in women in East Asia with moderate-to-severe vasomotor 579 symptoms associated with menopause. Menopause. 2022;29(5):553-63. 580 11. Freeman EW, Sammel MD, Sanders RJ. Risk of long-term hot flashes after 581 natural menopause: evidence from the Penn Ovarian Aging Study cohort. Menopause. 2014;21(9):924-32. 582 Williams RE, Kalilani L, DiBenedetti DB, Zhou X, Granger AL, Fehnel SE, et al. 583 12. 584 Frequency and severity of vasomotor symptoms among peri- and postmenopausal women in 585 the United States. Climacteric. 2008;11(1):32-43. 586 Avis NE, Crawford SL, Greendale G, Bromberger JT, Everson-Rose SA, Gold 13. 587 EB, et al. Duration of menopausal vasomotor symptoms over the menopause transition. 588 JAMA Intern Med. 2015;175(4):531-9. Tomida M, Otsuka R, Tange C, Nishita Y, Kimura T, Stoelzel M, et al. 589 14. 590 Vasomotor symptoms, sleep problems, and depressive symptoms in community-dwelling 591 Japanese women. J Obstet Gynaecol Res. 2021;47(10):3677-90. 592 Cho L, Kaunitz AM, Faubion SS, Hayes SN, Lau ES, Pristera N, et al. 15. Rethinking Menopausal Hormone Therapy: For Whom, What, When, and How Long? 593 594 Circulation. 2023;147(7):597-610. Kalantaridou SN, Naka KK, Papanikolaou E, Kazakos N, Kravariti M, Calis KA, 595 16. 596 et al. Impaired endothelial function in young women with premature ovarian failure: 597 normalization with hormone therapy. J Clin Endocrinol Metab. 2004;89(8):3907-13. 598 Pinna C, Cignarella A, Sanvito P, Pelosi V, Bolego C. Prolonged ovarian 17. 599 hormone deprivation impairs the protective vascular actions of estrogen receptor alpha 600 agonists. Hypertension. 2008;51(4):1210-7.

601 18. Hodis HN, Mack WJ, Henderson VW, Shoupe D, Budoff MJ, Hwang-Levine J, 602 et al. Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol. N Engl 603 J Med. 2016;374(13):1221-31. 604 19. Nappi RE. The 2022 hormone therapy position statement of The North 605 American Menopause Society: no news is good news. Lancet Diabetes Endocrinol. 606 2022;10(12):832-4. 607 20. Liu T, Chen S, Mielke GI, McCarthy AL, Bailey TG. Effects of exercise on 608 vasomotor symptoms in menopausal women: a systematic review and meta-analysis. 609 Climacteric. 2022;25(6):552-61. 610 21. Franco OH, Muka T, Colpani V, Kunutsor S, Chowdhury S, Chowdhury R, et al. 611 Vasomotor symptoms in women and cardiovascular risk markers: Systematic review and 612 meta-analysis. Maturitas. 2015;81(3):353-61. 613 Ryu KJ, Park H, Park JS, Lee YW, Kim SY, Kim H, et al. Vasomotor symptoms 22. 614 and carotid artery intima-media thickness among Korean midlife women. Maturitas. 615 2022;159:1-6. 616 23. Thurston RC, Chang Y, Barinas-Mitchell E, Jennings JR, Landsittel DP, 617 Santoro N, et al. Menopausal Hot Flashes and Carotid Intima Media Thickness Among 618 Midlife Women. Stroke. 2016;47(12):2910-5. 619 Thurston RC, Kuller LH, Edmundowicz D, Matthews KA. History of hot flashes 24. 620 and aortic calcification among postmenopausal women. Menopause. 2010;17(2):256-61. 621 25. Thurston RC, Aslanidou Vlachos HE, Derby CA, Jackson EA, Brooks MM, 622 Matthews KA, et al. Menopausal Vasomotor Symptoms and Risk of Incident Cardiovascular 623 Disease Events in SWAN. J Am Heart Assoc. 2021;10(3):e017416. 624 26. Zhu D, Chung HF, Dobson AJ, Pandeya N, Anderson DJ, Kuh D, et al. 625 Vasomotor menopausal symptoms and risk of cardiovascular disease: a pooled analysis of 626 six prospective studies. Am J Obstet Gynecol. 2020;223(6):898 e1- e16. 627 27. Bergstrom G, Persson M, Adiels M, Bjornson E, Bonander C, Ahlstrom H, et al. 628 Prevalence of Subclinical Coronary Artery Atherosclerosis in the General Population. 629 Circulation. 2021;144(12):916-29. 630 28. Greene JG. A factor analytic study of climacteric symptoms. J Psychosom Res. 631 1976;20(5):425-30. 632 29. Bergstrom G, Berglund G, Blomberg A, Brandberg J, Engstrom G, Engvall J, et 633 al. The Swedish CArdioPulmonary BioImage Study: objectives and design. J Intern Med. 634 2015;278(6):645-59. 635 30. Budoff MJ, Cohen MC, Garcia MJ, Hodgson JM, Hundley WG, Lima JA, et al. 636 ACCF/AHA clinical competence statement on cardiac imaging with computed tomography 637 and magnetic resonance: a report of the American College of Cardiology 638 Foundation/American Heart Association/American College of Physicians Task Force on 639 Clinical Competence and Training, J Am Coll Cardiol. 2005;46(2):383-402. 640 Ohnesorge B, Flohr T, Fischbach R, Kopp AF, Knez A, Schroder S, et al. 31. 641 Reproducibility of coronary calcium quantification in repeat examinations with retrospectively 642 ECG-gated multisection spiral CT. Eur Radiol. 2002;12(6):1532-40. 643 32. Prahl U, Holdfeldt P, Bergstrom G, Fagerberg B, Hulthe J, Gustavsson T. 644 Percentage white: a new feature for ultrasound classification of plaque echogenicity in 645 carotid artery atherosclerosis. Ultrasound Med Biol. 2010;36(2):218-26. 646 33. Ostling G, Persson M, Hedblad B, Goncalves I. Comparison of grey scale 647 median (GSM) measurement in ultrasound images of human carotid plaques using two different softwares. Clin Physiol Funct Imaging. 2013;33(6):431-5. 648 649 34. Ekblom O, Ekblom-Bak E, Bolam KA, Ekblom B, Schmidt C, Soderberg S, et al. 650 Concurrent and predictive validity of physical activity measurement items commonly used in 651 clinical settings--data from SCAPIS pilot study. BMC Public Health. 2015;15:978. 652 35. Thurston RC, Johnson BD, Shufelt CL, Braunstein GD, Berga SL, Stanczyk FZ, 653 et al. Menopausal symptoms and cardiovascular disease mortality in the Women's Ischemia 654 Syndrome Evaluation (WISE). Menopause. 2017;24(2):126-32.

655 36. Miller VM, Kling JM, Files JA, Joyner MJ, Kapoor E, Moyer AM, et al. What's in 656 a name: are menopausal "hot flashes" a symptom of menopause or a manifestation of 657 neurovascular dysregulation? Menopause. 2018;25(6):700-3. 658 37. Thurston RC, Matthews KA, Chang Y, Santoro N, Barinas-Mitchell E, von Kanel R, et al. Changes in heart rate variability during vasomotor symptoms among midlife women. 659 660 Menopause. 2016;23(5):499-505. 661 38. Reed SD, Newton KM, Larson JC, Booth-LaForce C, Woods NF, Landis CA, et al. Daily salivary cortisol patterns in midlife women with hot flashes. Clin Endocrinol (Oxf). 662 663 2016;84(5):672-9. 664 39. Sauer T, Tottenham LS, Ethier A, Gordon JL. Perimenopausal vasomotor 665 symptoms and the cortisol awakening response. Menopause. 2020;27(11):1322-7. Kronenberg F. Menopausal hot flashes: a review of physiology and 666 40. biosociocultural perspective on methods of assessment. J Nutr. 2010;140(7):1380S-5S. 667 41. Freedman RR. Menopausal hot flashes: mechanisms, endocrinology, 668 669 treatment. J Steroid Biochem Mol Biol. 2014;142:115-20. Mehta A, Pandey A, Ayers CR, Khera A, Sperling LS, Szklo MS, et al. 670 42. 671 Predictive Value of Coronary Artery Calcium Score Categories for Coronary Events Versus Strokes: Impact of Sex and Race: MESA and DHS. Circ Cardiovasc Imaging. 672 673 2020;13(8):e010153. 674 43. Achenbach S, Raggi P. Imaging of coronary atherosclerosis by computed 675 tomography. Eur Heart J. 2010;31(12):1442-8. Jashari F, Ibrahimi P, Nicoll R, Bajraktari G, Wester P, Henein MY. Coronary 676 44. and carotid atherosclerosis: similarities and differences. Atherosclerosis. 2013;227(2):193-677 678 200. 679 45. Touze E, Varenne O, Calvet D, Mas JL. Coronary risk stratification in patients 680 with ischemic stroke or transient ischemic stroke attack. Int J Stroke. 2007;2(3):177-83. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick 681 46. 682 ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: 683 principal results From the Women's Health Initiative randomized controlled trial. JAMA. 684 2002;288(3):321-33. 47. Rosengren A, Hawken S, Ounpuu S, Sliwa K, Zubaid M, Almahmeed WA, et al. 685 686 Association of psychosocial risk factors with risk of acute myocardial infarction in 11119 687 cases and 13648 controls from 52 countries (the INTERHEART study): case-control study. 688 Lancet. 2004;364(9438):953-62. Partinen M, Gislason T. Basic Nordic Sleep Questionnaire (BNSQ): a 689 48. 690 quantitated measure of subjective sleep complaints. J Sleep Res. 1995;4(S1):150-5. 691 Bohn MJ, Babor TF, Kranzler HR. The Alcohol Use Disorders Identification Test 49. 692 (AUDIT): validation of a screening instrument for use in medical settings. J Stud Alcohol. 693 1995:56(4):423-32. 694 Patten SB, Brandon-Christie J, Devji J, Sedmak B. Performance of the 50. 695 composite international diagnostic interview short form for major depression in a community

696 sample. Chronic Dis Can. 2000;21(2):68-72.

697

699 Tables

Table 1. General characteristics by VMS category of the study population,

701 SCAPIS (n = 2995)

Characteristics	Never/mild n = 2027 67.7%	Moderate n = 543 18.1%	Severe n = 425 14.2%
Age, mean (SD) [†]	58.3 (4.2)	57.7 (4.3)	58.4 (4.1)
Born outside Sweden, n (%)	230 (11.5)	53 (9.9)	74 (17.7) [#]
University degree , n (%) [*]	1012 (50.7)	285 (53.3)	176 (42.1) ^{II}
Currently working, n (%) [*]	1681 (83.9)	462 (86.4)	345 (82.3)
Financial strain, n (%) [*]	62 (3.1)	18 (3.4)	28 (6.7) [#]
Smoking status, n (%) [*]			
Past	753 (38.1)	217 (40.9)	197 (48.0) [#]
Current	209 (10.6)	68 (12.8)	55 (13.4)
Pack years for cigarettes, median $(25^{th} - 75^{th} \text{ percentile})^{\ddagger}$	10.5 (4.5 – 19.5)	11.8 (5.0 – 21.0)	13.3 (5.5 – 21.0) [§]
Medical history, n (%) [*]			
Ischemic heart disease	39 (1.9)	5 (0.9)	4 (0.9)
Ischemic stroke	41 (2.0)	11 (2.0)	6 (1.4)
Hypertension	353 (17.4)	93 (17.1)	80 (18.8)
Hyperlipidemia	166 (8.2)	31 (5.7)	24 (5.6)
Diabetes mellitus	78 (3.8)	14 (2.6)	16 (3.8)
Sleep apnea	45 (2.2)	8 (1.5)	12 (2.8)
Family history, n (%) [*]			
Myocardial infarction	144 (7.2)	32 (6.0)	32 (7.7)
Stroke	126 (6.3)	30 (5.6)	40 (9.6) [§]

Overweight (25-29.9 kg/m²) , n (%) [*]	711 (35.1)	224 (41.3)	181 (42.6)
Obese (≥30 kg/m²) , n (%) [°]	379 (18.7)	83 (15.3)	79 (18.6)
Waist circumference (cm), mean (SD) [†]	89.0 (12.9)	88.8 (11.7)	89.6 (11.7)
Blood pressure (mmHg), mean (SD) [†]			
Systolic blood pressure [†]	128 (18)	128 (18)	128 (19)
Systolic blood pressure >140, n (%) [*]	490 (24.2)	127 (23.4)	102 (24.0)
Diastolic blood pressure [†]	81 (11)	81 (10)	80 (11)
Diastolic blood pressure >90, n (%)	399 (19.7)	98 (18.0)	78 (18.4)
Cardiometabolic biomarkers			
LDL cholesterol (mmol/L), mean $(SD)^{\dagger}$	3.3 (1.0)	3.3 (0.9)	3.3 (1.0)
Triglycerides (mmol/L), mean (SD) †	1.0 (5.3)	1.0 (0.5)	1.1 (0.7)
hsCRP (mg/L), median (25 th – 75 th percentile) [‡]	0.9 (0.6 – 2.1)	0.9 (0.6 – 1.9)	1.1 (0.6 – 2.2)
HbA1c (mmol/mol) Mean $(SD)^{\dagger}$	36.6 (5.9)	36.3 (3.9)	36.6 (5.7)
Subjective experience of bad or very bad sleep, n (%) *	281 (14.2)	106 (20.1)	118 (28.9) [#]
Physical activity, mean $(SD)^{\dagger}$			
Sedentary	51.6 (10.0)	51.4 (9.7)	50.0 (9.7)
Moderate/vigorous activity	6.7 (3.4)	6.8 (3.3)	6.5 (3.6)
High alcohol consumption, n (%) $$	160 (8.9)	76 (15.4) [#]	45 (12.3)
Continuous stress last 1-5 years, n (%)	463 (23.5)	155 (29.2)	133 (32.6) [#]
Depression, n (%)	405 (20.3)	146 (27.3) [#]	120 (29.2) [#]

702 All statistical comparisons have the never/mild group as reference category. SCAPIS = Swedish

703 CArdioPulmonary bioImage Study; VMS = Vasomotor symptoms; SBP = Systolic blood pressure; DBP = Diastolic

blood pressure; LDL = Low density lipoprotein; hsCRP = high sensitivity C-reactive protein. * Chi2 test; [†] Independent T-test; [‡] Mann-Whitney U test; [§] p < 0.05; ^{||} p < 0.01; [#] p < 0.001. 704

Characteristics	Never/mild n = 2027 67.7%	Moderate n = 543 18.1%	Severe n = 425 14.2%
Menopausal status, n (%)			
Perimenopausal	225 (11.1)	54 (9.9)	28 (6.6) [#]
Postmenopausal	1802 (88.9)	489 (90.1)	397 (93.4) [#]
Early postmenopausal (0-3 yrs)	338 (20.4)	114 (25.6)	72 (20.0)
Late postmenopausal (>3-6 yrs)	380 (23.0)	116 (26.0)	84 (23.3)
Very late postmenopausal (>6 yrs)	935 (56.6)	216 (48.4) [#]	204 (56.7)
Age at menopause, mean (SD) [†]	50.9 (3.6)	51.1 (3.5)	50.6 (4.1)
VMS, n (%) ^{*.§}			
Ongoing/current	642 (53.8)	296 (57.1)	235 (58.8)
Weekly last two weeks	119 (18.5)	50 (16.8)	21 (8.9)**
Daily last two weeks	187 (29.1)	185 (62.3)**	162 (68.6)**
Previous	551 (46.2)	222 (42.9)	165 (41.3)
Age at start of VMS, mean (SD) [†]	50.5 (6.1)	49.9 (5.6)	49.4 (6.4) [#]
Duration, years, median (25 th – 75 th percentile) [‡]	4.0 (2.0 - 6.0)	5.0 (3.0 - 8.0)**	6.0 (3.0 – 10.0) [°]
Other menopausal symptoms, n (%) $$	488 (24.3)	210 (38.9)**	178 (42.1)**
мнт			
Current, n (%)	98 (4.8)	72 (13.3)**	111 (26.1)**
Previous, n (%)	124 (6.1)	100 (18.4)**	103 (24.2)**
Start, age, mean (SD) [†]	51.6 (5.5)	51.4 (4.0)	50.9 (4.6)
Duration, years, median (25 th – 75 th percentile) [‡]	3.0 (1.0 – 5.0)	3.0 (1.0 – 5.0)	5.0 (2.0 – 7.0)*

Table 2. Reproduction-related characteristics by VMS category of the study population, SCAPIS (n = 2995)

Ever usage of herbal medicine (e.g., phytoestrogens) for VMS, n (%)	110 (5.5)	85 (16.0)**	85 (20.4)**
Medical obstetric history [*]			
Preeclampsia	107 (5.3)	25 (4.6)	22 (5.2)
Gestational hypertension	43 (2.1)	11 (2.0)	4 (0.9)
Gestational diabetes	51 (2.5)	10 (1.9)	7 (1.7)

708 All statistical comparisons have the never/mild group as reference category. SCAPIS = Swedish

709 CArdioPulmonary bioImage Study; VMS = Vasomotor symptoms; MHT = Menopausal hormone therapy. * Chi2

test; [†] Independent T-test; [‡] Mann-Whitney U test; [§] Women who never experienced VMS were not considered when reporting results for the 'Never/mild'-group; ^{||} p < 0.05 [#] p < 0.01 ** p < 0.001. 710

712	Table 3. Prevalence of subclinical ASCVD detected by CT, CCTA or	
-----	--	--

vultrasound by VMS category of the study population. SCAPIS (n = 2995)

Measures	Never/mild n = 2027 67.7 %	Moderate n = 543 18.1%	Severe n = 425 14.2%
CACS, n (%) [*]			
>0	578 (29.3)	137 (25.7)	143 (34.4) [§]
1-10	193 (9.8)	47 (8.8)	51 (12.3)
11-100	250 (12.7)	65 (12.2)	68 (16.3)
101-400	107 (5.4)	20 (3.7)	15 (3.6)
> 400	28 (1.4)	5 (0.9)	9 (2.2)
CACS [‡] , median (25 th – 75 th percentile) [†]	26.0 (6.0 – 92.0)	22 (6.5 – 75.5)	21 (6.0 – 71.0)
CCTA , n (%) [*]			
Any form of coronary atherosclerosis	516 (27.8)	130 (25.9)	135 (34.1) [§]
Any coronary stenosis ≥50%	28 (1.5)	4 (0.8)	6 (1.5)
SIS >3 [°]	84 (4.5)	16 (3.2)	20 (5.1)
Any carotid plaque, n (%)	942 (46.6)	255 (47.2)	202 (47.6)
Unilateral plaque	588 (29.1)	152 (28.1)	109 (25.7)
Bilateral plaques	354 (17.5)	103 (19.1)	93 (21.9) [§]

714 All statistical comparisons have the never/mild group as reference. SCAPIS = Swedish

715 CArdioPulmonary bioImage Study; VMS = Vasomotor symptoms; ASCVD = Atherosclerotic

716 cardiovascular disease; CT = Computed tomography; CCTA = Coronary computed tomography

717 angiography; CACS = Coronary artery calcium score; SIS = Segment involvement score. * Chi2 test *

718 Mann-Whitney U test; [‡] Calculation based on the participants with a CAC score >0; p < 0.05.



